Lexeo Therapeutics
LXEO
142 hedge funds and large institutions have $411M invested in Lexeo Therapeutics in 2026 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 59 increasing their positions, 39 reducing their positions, and 22 closing their positions.
51% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 39
27% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 22
2.92% more ownership
Funds ownership: 109.46% → 112.38% (+2.9%)
2% more funds holding
Funds holding: 139 → 142 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
10% less capital invested
Capital invested by funds: $459M → $411M (-$47.9M)
66% less call options, than puts
Call options by funds: $83K | Put options by funds: $243K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
+$27.8M |
| 2 |
Millennium Management
New York
|
+$6.6M |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$4.93M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$4.45M |
| 5 |
State Street
Boston,
Massachusetts
|
+$4.25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
-$10.9M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$9.65M |
| 3 |
OCA
Octagon Capital Advisors
New York
|
-$6.31M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
-$2.09M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$1.35M |
LXEO Hedge Fund Activity: Q2 2026 in Review
142 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Lexeo Therapeutics (LXEO) for Q2 2026, worth a combined $411M — down 10% from $459M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new LXEO positions and 22 closed out — a net gain of 6 holders — while 59 added to existing stakes and 39 trimmed.
The largest buyer was Suvretta Capital Management, adding an estimated $27.8M. The largest seller was Paradigm Biocapital Advisors, cutting an estimated $10.9M.
- 142 institutional investors held Lexeo Therapeutics (LXEO) as of Q2 2026, up from 139 in Q1 2026.
- Funds reported $411M of Lexeo Therapeutics stock for Q2 2026, down 10% quarter-over-quarter.
- 28 funds opened new Lexeo Therapeutics positions in Q2 2026 and 22 closed out, a net change of +6 holders.
- The largest Lexeo Therapeutics buyer in Q2 2026 was Suvretta Capital Management, an estimated $27.8M added.
- The largest Lexeo Therapeutics seller in Q2 2026 was Paradigm Biocapital Advisors, an estimated $10.9M sold.
Based on aggregated 13F filings for Q2 2026.